Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
AKUMS •NSE
Akums Drugs & Pharmaceuticals
₹779.052.35 (0.30%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Performance
Today’s low
771.30
Today’s high
796.55
52 week low
409.30
52 week high
796.55
Open price
780.50
Previous close
776.70
Live volume
4,61,075
Lower circuit
701.15
Upper circuit
856.95
Fundamentals
Market Cap
₹12,261Cr
ROE
7.70%
P/E Ratio(TTM)
41.88
EPS(TTM)
18.60
P/B Ratio
3.70
Dividend Yield
0.37%
Industry P/E
38.05
Book Value
210.57
Debt to Equity
0.05
Face Value
2
Financial performance
JUN '26
Revenue (Cr)
₹1,197
+0.32%
Profit (Cr)
₹101
+24.15%
03006009001.2k
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
| Revenue growth | Value |
|---|---|
| 1Y (TTM) | +14% |
| 3Y CAGR | +6% |
| Profit growth | Value |
|---|---|
| 1Y (TTM) | +56% |
| 3Y CAGR | +38% |
About
Akums Drugs & Pharmaceuticals Limited is a contract manufacturing pharmaceutical company producing formulations for various therapies.;
CEO/MD
Sanjeev Jain
Founded in
2004
NSE symbol
AKUMS
Shareholding pattern
Mutual Funds Invested (4)
Similar stocks
| Stock | Mkt price (1D) | 52 week performance | Market cap | P/E ratio | P/B ratio | |
|---|---|---|---|---|---|---|
Neuland LaboratoriesNEULANDLAB | ₹23,025.00 +15.00 (0.07%) | 29,554.93 | 59.37 | 15.77 | ||
Piramal PharmaPPLPHARMA | ₹213.20 -1.20 (0.56%) | 28,384.34 | -- | 3.48 | ||
Cohance LifesciencesCOHANCE | ₹460.00 +4.05 (0.89%) | 17,589.91 | 300.49 | 4.5 | ||
Onesource Specialty PharmaONESOURCE | ₹1,527.90 +8.80 (0.58%) | 17,501.95 | -- | 3 |
Livesquawk •
Akums Drugs to hold analyst, investor meeting on Sept 2.
Livesquawk •
Citi maintains Accumulate on Akums Drugs with a ₹860 target, citing improved CDMO earnings quality.
Stronger API pricing outlook could drive 5–10% EPS upgrades for FY27–28.
Livesquawk •
Akums Drugs targets API segment to achieve monthly EBITDA positivity by Feb/Mar FY27.
API segment expected to contribute positively to corporate from FY28.
Livesquawk •
Akums secures Zambia order worth INR 240 crore, reflecting in H2 FY27.
European business operations expected to commence in FY28.
Livesquawk •
Akums expects domestic branded formulations to improve from Q3 FY27.
International branded formulations segment projected to return to growth soon.
Livesquawk •
Akums Drugs expects robust FY27 performance with strong CDMO growth.
CDMO segment likely to see double-digit growth; Q2 growth in high teens.
2026
8
Aug
Result
Release date
3JulDividendEx date₹1.00per share
3
Jul
Dividend
Ex date
₹1.00
per share
For each share you hold, you will receive ₹1.00
Dividend amount₹1.00 per share
Dividend TypeFinal
Ex Date3 Jul ‘26
Record Date3 Jul ‘26
Announcement date14 May ‘26
3JulDividendEx date₹2.00per share
3
Jul
Dividend
Ex date
₹2.00
per share
For each share you hold, you will receive ₹2.00
Dividend amount₹2.00 per share
Dividend TypeSpecial
Ex Date3 Jul ‘26
Record Date3 Jul ‘26
Announcement date14 May ‘26
14MayDividendAnnounced₹1.00per share
14
May
Dividend
Announced
₹1.00
per share
For each share you hold, you will receive ₹1.00
Dividend amount₹1.00 per share
Dividend TypeFinal
Ex Date3 Jul ‘26
Record Date3 Jul ‘26
Announcement date14 May ‘26
14MayDividendAnnounced₹2.00per share
14
May
Dividend
Announced
₹2.00
per share
For each share you hold, you will receive ₹2.00
Dividend amount₹2.00 per share
Dividend TypeSpecial
Ex Date3 Jul ‘26
Record Date3 Jul ‘26
Announcement date14 May ‘26
14
May
Quarterly & Annual Result
Release date
13
Feb
Quarterly Result
Release date
2025
13
Nov
Quarterly Result
Release date
8
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks